The FDA has signed off on a Phase 2/3 clinical trial evaluating PTC Therapeutics’ (NASDAQ:PTCT) PTC299, an oral dihydroorotate dehydrogenase (DHODH) inhibitor, for the potential treatment of COVID-19.
The company says the candidate has two mechanisms
of action for treating the infection: addressing high viral replication
and the subsequent uncontrolled inflammatory response.
The first stage of the study, expected to launch
in the coming days, will enroll 40 hospitalized adult patients, followed
by a larger cohort of ~340.
The primary objective will be time to respiratory improvement.
Management hosted a conference call this morning at 8:30 am ET to discuss the trial.
https://seekingalpha.com/news/3583682-ptc-therapeutics-launches-study-of-ptc299-in-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.